Finally, we found that high SPNS3 expression positively correlated with AML relapse (P = 0.043), death (P = 0.023), FLT3-ITD mutation (P < 0.000), WT1 mutation (P = 0.030), and minimal residual disease (MRD) at end of course 2 (P < 0.000) and negatively correlated with EFS (P = 0.019), t(8;21) chromosomal abnormality (P = 0.001), cytogenetic complexity (P = 0.046), complete remission (CR) at end of course 2 (P < 0.000) (Table 1). This evidence concerns the gene SPNS3 and acute myeloid leukemia.